Throughout this proposal, we have emphasized the need to move research findings into the clinic. The new Shared Resource and Methodology dispussed below will provide important new areas of expertise needed by our investigators on both sides of the clinical interface. In order to link the developing shared resources with our Cancer Center members, we propose to use CCSG pilot project support specifically for projects that utilize the new shared resources. TRANSLATIONAL METHODOLOGY PILOT FUNDING! In order to fully utilize the capabilities of the Translational Methodology, we will create a new mechanism for pilot support designed to move a project through from discovery to drug scale-up. Support for a single project funded at $100,000 per year for one year will help ensure that new cancer therapeutics are using this methodology. CLINICAL PHARMACOLOGY PILOT SUPPORT New therapies may fail for many reasons. We are beginning to understand how pharmacokinetics affect benefit and toxicity of many new drugs. Many clinical studies frequently do not incorporate pharmacokinetic, pharmaCodynamic, or pharmacogenetic evaluation into their trial design because of cost. In this pilot mechanism, we will offer support for these types of studies in investigator-initiated clinical trials. The purpose of this mechanism of pilot support is not meant to fund the entire clinical trial Instead, this pilot funding will serve as a supplement to ongoing clinical trials. A total amount of $50,000 per year is committed to this program from CCSG funds. There will be no uniform date for application for this mechanism given the nature of clinical investigation. Instead, this mechanism will be promoted to the Cancer Center membership, and a review of each proposal will be initiated by the Clinical Research Leadership committee and Drs. Jacobson and Kirstein. If the study is deemed to be of sufficient merit, then it will be funded and funds will be expended on a first-come, first-served basis. Other meritorious trials can be supported by philanthropic funds if they are proposed after the CCSG support is committed. In addition to these specific mechanisms, the existing pilot project support will be maintained (TTURC, Women's Cancer, Brainstorm, Population Science, Sarcoma). The CCSG will support some of these mechanisms and may be supplemented with philanthropic support. ONGOING SUPPORT OF EXISTING AWARD MECHANISMS We propose to continue to bur annual Brainstorm awards to promote interprogrammatic research, as well as specific awards in the areas of population sciences and translational research. Although the majority of these awards will be funded through philanthropic support, we have budgeted $200,000 in CCSG support.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Abbott, Kenneth L; Nyre, Erik T; Abrahante, Juan et al. (2015) The Candidate Cancer Gene Database: a database of cancer driver genes from forward genetic screens in mice. Nucleic Acids Res 43:D844-8
Yee, Douglas (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21:667-9
Daniel, A R; Gaviglio, A L; Knutson, T P et al. (2015) Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34:506-15
Upadhyaya, Pramod; Hecht, Stephen S (2015) Quantitative analysis of 3'-hydroxynorcotinine in human urine. Nicotine Tob Res 17:524-9
Patel, Yesha M; Stram, Daniel O; Wilkens, Lynne R et al. (2015) The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev 24:119-27
Takahashi, Yutaka; Hui, Susanta K (2014) Fast, simple, and informative patient-specific dose verification method for intensity modulated total marrow irradiation with helical tomotherapy. Radiat Oncol 9:34
Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600
Chen, Liddy M; Ibrahim, Joseph G; Chu, Haitao (2014) Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. J Biopharm Stat 24:817-33
Landman, Sean R; Hwang, Tae Hyun; Silverstein, Kevin A T et al. (2014) SHEAR: sample heterogeneity estimation and assembly by reference. BMC Genomics 15:84
Gates, Leah A; Phillips, Martin B; Matter, Brock A et al. (2014) Comparative metabolism of furan in rodent and human cryopreserved hepatocytes. Drug Metab Dispos 42:1132-6

Showing the most recent 10 out of 319 publications